{"groups":[{"description":"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).\n\nArm 1 contains patients treated as dose level 1 (50 x 10\\^6 EGFRt cells)\n\nAutologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143: Given IV\n\nCyclophosphamide: Given IV\n\nFludarabine: Given IV\n\nLeukapheresis: Undergo leukapheresis","id":"FG000","title":"Treatment (Chemotherapy, BCMA CAR-T Cells) at Dose Level 1"},{"description":"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).\n\nArm 2 contains patients treated as dose level 2 (150 x 10\\^6 EGFRt cells)\n\nAutologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143: Given IV\n\nCyclophosphamide: Given IV\n\nFludarabine: Given IV\n\nLeukapheresis: Undergo leukapheresis","id":"FG001","title":"Treatment (Chemotherapy, BCMA CAR-T Cells) at Dose Level 2"},{"description":"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).\n\nArm 3 contains patients treated as dose level 3 (300 x 10\\^6 EGFRt cells)\n\nAutologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143: Given IV\n\nCyclophosphamide: Given IV\n\nFludarabine: Given IV\n\nLeukapheresis: Undergo leukapheresis","id":"FG002","title":"Treatment (Chemotherapy, BCMA CAR-T Cells) at Dose Level 3"},{"description":"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).\n\nArm 4 contains patients treated as dose level 4 (450 x 10\\^6 EGFRt cells)\n\nAutologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143: Given IV\n\nCyclophosphamide: Given IV\n\nFludarabine: Given IV\n\nLeukapheresis: Undergo leukapheresis","id":"FG003","title":"Treatment (Chemotherapy, BCMA CAR-T Cells) at Dose Level 4"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"3"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"3 patients withdrew consent after enrollment and did not move on to treatment. These 3 patients were not assigned to a dose level."}